Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

3.66
-0.5900-13.88%
Pre-market: 3.700.0400+1.09%07:23 EDT
Volume:3.89M
Turnover:14.84M
Market Cap:315.54M
PE:-0.97
High:4.27
Open:4.27
Low:3.64
Close:4.25
52wk High:19.11
52wk Low:3.64
Shares:86.21M
Float Shares:60.67M
Volume Ratio:1.31
T/O Rate:6.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:1.90
PE(LYR):-1.16

Loading ...

EyePoint is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Aug 06

EyePoint price target lowered to $27 from $30 at H.C. Wainwright

TIPRANKS
·
Aug 06

Analyst Reiterates Buy on EYPT Ahead of Pivotal LUGANO Phase III Data and Favorable Risk‑Reward Profile

TIPRANKS
·
Aug 06

RxSight Q2 Adjusted Loss Beats Estimates; Withdraws 2026 Guidance

Reuters
·
Aug 06

Sight Sciences Q2 Revenue Rises 20%, Beats Estimates

Reuters
·
Aug 06

Arcus Biosciences Q2 Revenue Falls Sharply on Lower License Income

Reuters
·
Aug 06

Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
Aug 06

EyePoint Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

EyePoint Q2 2026 earnings: Phase 3 spending widens the net loss

TradingKey
·
Aug 05

EyePoint reports Q2 EPS ($1.09), consensus (96c)

TIPRANKS
·
Aug 05

EyePoint Pharmaceuticals Q2 EPS $(1.09) Misses $(0.95) Estimate, Sales $507.000K Beat $406.857K Estimate

Benzinga Earnings
·
Aug 05

EyePoint Pharmaceuticals Q2 Revenue Drops on Lower License Income

Reuters
·
Aug 05

EyePoint Q2 FY26 Net Loss Widens to $94.47 Million; Revenue Drops to $507,000

Reuters
·
Aug 05

EyePoint Pharmaceuticals Q2 Basic EPS USD -1.09

THOMSON REUTERS
·
Aug 05

EyePoint Pharmaceuticals Q2 Product Sales USD 507 Thousand

THOMSON REUTERS
·
Aug 05

EyePoint Completes Enrollment in Phase 3 Duravyu Diabetic Macular Edema Trials COMO, CAPRI

Reuters
·
Jul 30

EyePoint (EYPT) Settles DOJ Claims, Is The 71% Undervaluation Case Convincing?

Simply Wall St.
·
Jul 30

EyePoint - Phase 3 Wet Amd Program Data Anticipated Beginning August 2026

THOMSON REUTERS
·
Jul 30

EyePoint - Topline Data for Dme Phase 3 Trials Anticipated in Q4 2027

THOMSON REUTERS
·
Jul 30

EyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of Duravyu™ for Treatment of Diabetic Macular Edema (Dme)

THOMSON REUTERS
·
Jul 30